2 min read
Over the past three years, five multinational pharmaceutical companies have strategically shifted their manufacturing operations from Pakistan, the National Assembly was informed. Health Minister Syed Mustafa Kamal confirmed that these divestments are part of a global business strategy rather than closures, ensuring the continued supply of essential medicines under new local ownership.
The companies involved include:
- Bayer (Lahore unit)
- ICI Pakistan (multi-city operations)
- Sanofi-Aventis (Korangi plant)
- Pfizer (S.I.T.E. Karachi site)
- Novartis (West Wharf facility)
Minister Kamal emphasized that these moves aim to optimize operations while keeping production lines active. Lucky Core Industries, which acquired Pfizer’s local assets in 2024, reaffirmed its commitment to Pakistan’s pharmaceutical sector. Bayer also highlighted that it continues to operate in Pakistan, providing healthcare and consumer products, alongside its crop science division.
The strategic transitions illustrate how multinational firms are realigning local operations globally while sustaining healthcare access and supporting domestic pharmaceutical growth.
